Page last updated: 2024-11-04

vorinostat and Brain Damage, Chronic

vorinostat has been researched along with Brain Damage, Chronic in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Brain Damage, Chronic: A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, T1
Zhang, YM1
Han, D1
Hua, R1
Guo, BN1
Hu, SQ1
Yan, XL1
Xu, T1

Other Studies

1 other study available for vorinostat and Brain Damage, Chronic

ArticleYear
Involvement of IL-17 in Secondary Brain Injury After a Traumatic Brain Injury in Rats.
    Neuromolecular medicine, 2017, Volume: 19, Issue:4

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain Damage, Chronic; Brain Injuries, Traumatic;

2017